Canopy Growth (TSX:WEED): A Pot of Gold

Canopy Growth (TSX:WEED)(NYSE:CGC) is Canada’s leading producer and marketer of cannabis products and the first such company to be listed on both the Toronto and New York Stock Exchanges.

Consider the reasons why: a stellar management team committed to quality and innovation and to industry leadership through targeted acquisitions and alliances; a rapidly expanding international presence; and a recent investment of $5 billion by Constellation Brands, an American marketer of wine and beer that intends to develop cannabis-infused beverages.

The worldwide cannabis market is enormous. Estimates range from $100 billion to $500 billion a year. The lion’s share of this market — largely illegal — is for recreational use. A small percentage is for medical use, which is, in many places, also illegal. As legal acceptance continues to grow, Canopy Growth, I believe, is the company best positioned to maximize this massive opportunity.

With leading brands like Tweed and Tokyo Smoke, Canopy Growth is flourishing in the recreational market. However, smokable and edible cannabis products are essentially commodities, subject to the forces of supply and demand and fickle consumer loyalty.

Medical use, however, is a totally different market. It relies, for stability and growth, on patented products and proprietary technology. Thanks to its staff of research scientists, which already has 32 issued patents and over 140 patent applications, this burgeoning market, I believe, is where Canopy Growth is likely to reach its potential.

Millions of people stand to improve their quality of life with medical cannabis. It has already proven its worth in some critical areas — educing pain, for example, alleviating nausea from chemotherapy, controlling childhood epilepsy, and treating glaucoma and schizophrenia. With its arsenal of highly respected brands, Canopy Growth has emerged as a leader in this field, focused on both improving treatment and developing products to meet other medical needs.

Is Canopy Growth right for you? Here are some pros and cons…


The company’s outstanding management team has a sensible, multi-prong strategy for growth and a commitment to quality, innovation, and industry leadership. It’s a major player in both the recreational and medical markets, and its international marketing efforts are meeting with great success.

Not least, Canopy Growth’s financial health is superb. Beyond the investment by Constellation Brands, the company has little debt.

These factors give the company the flexibility to direct and control its growth. It can make more acquisitions, enhance its already robust R&D initiatives, or expand its international footprint. And they currently enable Canopy Growth to make these strategic choices without the need to issue more stock, which would dilute the market value of existing shares — a luxury for a young company.


The growth potential for cannabis products will surely increase competition, potentially affecting the company’s sales and profits. Fading brand loyalty can have a similar effect, as can over- or under-production, causing an imbalance in supply and demand. And growth may be slowed by government officials who continue to resist legalization.

Given Canopy Growth’s financial resources, reputation for quality, and  business acumen, I believe it can weather storms and continue to prosper.  I suggest you plant this potent weed in your equity portfolio.

5 TSX Stocks for Building Wealth After 50

BRAND NEW! For a limited time, The Motley Fool Canada is giving away an urgent new investment report outlining our 5 favourite stocks for investors over 50.

So if you’re looking to get your finances on track and you’re in or near retirement – we’ve got you covered!

You’re invited. Simply click the link below to discover all 5 shares we’re expressly recommending for INVESTORS 50 and OVER. To scoop up your FREE copy, simply click the link below right now. But you will want to hurry – this free report is available for a brief time only.

Click Here For Your Free Report!

More reading

Fool contributor Byron Alpers owns shares in Canopy.

Source: The Fool
Canopy Growth (TSX:WEED): A Pot of Gold
The Fool

The Motley Fool
Contributor for
The Motley Fool is dedicated to helping the world invest — better. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, mutual funds, and premium investing services.

In all we do, we take a different approach.

We believe – and have proven over decades – that the individual investor can beat the market.

We believe that anyone can do it, even if they don’t have a lot of time or money to devote to investing.

We believe in a long-term outlook, helping people build wealth over time.

We believe that the person best positioned to take care of your financial future is you.

And we work tirelessly on behalf of our hundreds of thousands of members who are enjoying the opportunities that come with having enough money to do the things that matter to them.

While we are headquartered in Alexandria, Va., The Motley Fool advocates for the individual investor around the globe with offices in the UK, Australia, Canada, Singapore, and Germany.

Related posts